PRESS RELEASE
April 20, 2007
World Renowned Scientist Dr. Ann de Wees Allen Joins Agel
Agel is pleased to announce that renowned scientist Dr. Ann de Wees Allen, Chief of Biomedical Research at the Glycemic Research Institute, has joined the Agel Team. Dr. Allen and Agel Enterprises will be introducing products that incorporate Dr. Allen’s L-arginine patents and Agel’s cutting edge “Suspension Gel Technology”.
Dr. Allen has been researching and patenting safe forms of L-arginine since 1983, and currently has the only technology for creating Blind Amino Acid Riders for L-arginine. Dr. Allen also received the first glycemic patent ever awarded worldwide.
Agel began operations in 2005 and has announced business operations in 43 countries. “Our Suspension Gel Technology combined with Dr. Allen’s products will open a whole new vista of opportunity for Agel Team Members globally”, said Glen Jensen, Agel CEO and founder.
Because this opportunity has presented itself so quickly, Agel has not had time to develop a product that combines Dr. Allen’s patented L-arginine and Agel’s suspension gel. For this reason, Agel will begin offering Dr. Allen’s L-arginine as a powder in order to fill present product demand while it develops a gel based product to replace the powder.
Once the gel based product is finished development, it will be available to team members worldwide.
Dr. Allen stated, “I am thrilled to be working with Agel. Together, we will make a real difference in the field of nutrition and anti-aging.”
Dr. Allen will also serve as Head of the Medical Advisory Board at Agel.
A list of Dr. Allen’s Bio and patents can be seen at:
www.AnndeWeesAllen.com
www.GlycemicResearchLaboratories.com
Subscribe to:
Post Comments (Atom)
Agel
No comments:
Post a Comment